Opinion

Video

Outlining the Current First-Line Treatment Landscape in Metastatic Urothelial Cancer: Starting With a Cisplatin-Ineligible Patient Case

Thomas Powles, MBBS, MRCP, MD, discusses how upon examining an elderly patient experiencing hematuria, they were found to have had a transurethral resection of a bladder tumor, which revealed the presence of muscle-invasive bladder cancer. The patient is determined to have metastatic disease and is ineligible for cisplatin chemotherapy in the first line.

Related Videos
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video